Implanted Brain-Computer Interface Devices Market to Grow by 10% Annually

North America leads the global market as neurological disorders drive demand for advanced neuroprosthetic solutions

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

The implanted brain-computer interface devices market is projected to grow at a CAGR of around 10% by 2032, driven by the rising incidence of neurological and movement disorders, as well as the increasing use of digital health technologies. North America is the largest regional market, benefiting from strong R&D funding, early adoption of neurotech, and the presence of leading companies in the space.

Why it matters

Implanted brain-computer interface (BCI) devices enable direct communication between neural activity and external technology, helping people with neurological disorders, paralysis, or sensory impairments. The rapid advancements in this field, including improved electrode materials, minimally invasive implantation techniques, and better signal processing, are transforming patient care and opening up new applications beyond medicine.

The details

The growth of the implanted BCI devices market is largely propelled by the rising prevalence of conditions like epilepsy, Parkinson's disease, and stroke, which create demand for advanced neuroprosthetic solutions. Additionally, the expanding use of digital health technologies is accelerating the market's advancement. Key factors driving the market include growing investment in neuroscience research, increasing adoption of BCIs in healthcare, and technological convergence enabling more effective and scalable implanted devices.

  • In August 2025, Neuralink revealed it would launch a clinical trial in Great Britain to evaluate its brain implant in individuals with severe paralysis.
  • In May 2025, IONWARD Medical implanted its ARC-BCI® therapy in two additional patients, raising the total number of recipients to five.
  • In May 2025, a €4 million grant was awarded to INBRAIN Neuroelectronic by the Spanish Ministry of Industry and Tourism through the PERTE Chip program.
  • In April 2025, Precision Neuroscience's primary brain-implant technology had been cleared by the U.S. FDA for restricted implantation and commercial application.

The players

NeuroPace, Inc.

A medical device company that develops and commercializes implantable neuromodulation devices, including the RNS System for the treatment of drug-resistant epilepsy.

Blackrock Neurotech

A leading provider of brain-computer interface technology, offering a range of implantable and non-invasive neural interface products for research and clinical applications.

Synchron

A neurotechnology company developing an implantable brain-computer interface called the Stentrode, designed to restore movement and communication for patients with paralysis.

LivaNova, Inc.

A global medical technology company that develops and commercializes innovative therapeutic solutions, including neuromodulation devices for the treatment of drug-resistant epilepsy and depression.

BrainGate

A research consortium focused on developing brain-computer interface technology to restore communication, mobility, and independence for people with neurological disorders or limb paralysis.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The rapid growth of the implanted brain-computer interface devices market highlights the transformative potential of neurotechnology in addressing a wide range of neurological and sensory impairments. As these advanced solutions become more accessible, they promise to significantly improve the quality of life for patients and unlock new frontiers in human-machine interaction.